EARNEST Partners’s Harvard Bioscience HBIO Stock Holding History

EARNEST Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-260	Closed	-$11.2K	–	632
2023 Q3	$11.2K	Hold	260	–	–	﹤0.01%	607
2023 Q2	$14.3K	Hold	260	–	–	﹤0.01%	555
2023 Q1	$10.9K	Hold	260	–	–	﹤0.01%	604
2022 Q4	$7.2K	Hold	260	–	–	﹤0.01%	691
2022 Q3	$7K	Hold	260	–	–	﹤0.01%	677
2022 Q2	$9K	Hold	260	–	–	﹤0.01%	625
2022 Q1	$16K	Hold	260	–	–	﹤0.01%	541
2021 Q4	$18K	Hold	260	–	–	﹤0.01%	523
2021 Q3	$18K	Hold	260	–	–	﹤0.01%	508
2021 Q2	$22K	Hold	260	–	–	﹤0.01%	454
2021 Q1	$14K	Hold	260	–	–	﹤0.01%	546
2020 Q4	$11K	Hold	260	–	–	﹤0.01%	587
2020 Q3	$8K	Hold	260	–	–	﹤0.01%	622
2020 Q2	$8K	Hold	260	–	–	﹤0.01%	609
2020 Q1	$6K	Hold	260	–	–	﹤0.01%	624
2019 Q4	$8K	Hold	260	–	–	﹤0.01%	631
2019 Q3	$8K	Hold	260	–	–	﹤0.01%	620
2019 Q2	$5K	Hold	260	–	–	﹤0.01%	762
2019 Q1	$11K	Hold	260	–	–	﹤0.01%	550
2018 Q4	$8K	Hold	260	–	–	﹤0.01%	592
2018 Q3	$14K	Hold	260	–	–	﹤0.01%	500
2018 Q2	$14K	Hold	260	–	–	﹤0.01%	497
2018 Q1	$13K	Hold	260	–	–	﹤0.01%	504
2017 Q4	$9K	Buy	+260	New	+$8.78K	﹤0.01%	581
2017 Q1	–	Sell	-260	Closed	-$8K	–	518
2016 Q4	$8K	Hold	260	–	–	﹤0.01%	572
2016 Q3	$7K	Hold	260	–	–	﹤0.01%	355
2016 Q2	$7K	Hold	260	–	–	﹤0.01%	357
2016 Q1	$8K	Hold	260	–	–	﹤0.01%	362
2015 Q4	$9K	Hold	260	–	–	﹤0.01%	352
2015 Q3	$10K	Hold	260	–	–	﹤0.01%	348
2015 Q2	$15K	Hold	260	–	–	﹤0.01%	317
2015 Q1	$15K	Hold	260	–	–	﹤0.01%	317
2014 Q4	$15K	Hold	260	–	–	﹤0.01%	324
2014 Q3	$11K	Hold	260	–	–	﹤0.01%	347
2014 Q2	$12K	Hold	260	–	–	﹤0.01%	353
2014 Q1	$12K	Sell	260 -120	-32%	-$5.46K	﹤0.01%	349
2013 Q4	$18K	Buy	+380	New	+$16.6K	﹤0.01%	353

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.46B AUM 78.13% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

EARNEST Partners's HBIO Position: Q4 2023 in Review

EARNEST Partners sold out of Harvard Bioscience (HBIO) in Q4 2023, closing a stake of 260 shares — an estimated $11.2K sold.

EARNEST Partners first reported a position in HBIO in Q4 2013 and held it in 37 quarters. The position peaked at $22K in Q2 2021. 93 funds tracked by Wall St. Rank hold HBIO as of Q4 2023.

EARNEST Partners reported no remaining Harvard Bioscience position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 260 Harvard Bioscience shares in Q4 2023, an estimated $11.2K.
EARNEST Partners first reported a position in Harvard Bioscience in Q4 2013 and held it in 37 quarters.
EARNEST Partners's Harvard Bioscience position peaked at $22K in Q2 2021.
93 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.